E2F3 gene expression is a potential negative prognostic marker for localised and MYCN not‐amplified neuroblastoma: Results of in silico analysis of 786 samples

Neuroblastoma (NB) is an enigmatic childhood malignancy characterised by a wide range of clinical behaviour. Many potential oncogenes for NB have recently been identified. Among them, E2 transcription factor 3 (E2F3) expression was associated with a poor survival in 134 stage 4S patients, but evidence for other stage groups remains poorly investigated.

[1]  M. Ohira,et al.  Loss of p53 suppresses replication stress-induced DNA damage in ATRX-deficient neuroblastoma , 2021, Oncogenesis.

[2]  F. Westermann,et al.  Neuroblastoma—Telomere maintenance, deregulated signaling transduction and beyond , 2021, International journal of cancer.

[3]  Hong Liu,et al.  MiR-493-5p inhibits the malignant development of gliomas via suppressing E2F3-mediated dysfunctions of P53 and PI3K/AKT pathways , 2021, Clinical and Translational Oncology.

[4]  Ting Ye,et al.  Emerging Role of E2F Family in Cancer Stem Cells , 2021, Frontiers in Oncology.

[5]  H. Saavedra,et al.  E2F3 drives the epithelial-to-mesenchymal transition, cell invasion, and metastasis in breast cancer , 2021, Experimental biology and medicine.

[6]  T. Kamijo,et al.  How Do Telomere Abnormalities Regulate the Biology of Neuroblastoma? , 2021, Biomolecules.

[7]  Zhaohui Xu,et al.  An Update on the Potential Roles of E2F Family Members in Colorectal Cancer , 2021, Cancer management and research.

[8]  J. Bertino,et al.  Anti-Tumor Effects of a Penetratin Peptide Targeting Transcription of E2F-1, 2 and 3a Is Enhanced When Used in Combination with Pemetrexed or Cisplatin , 2021, Cancers.

[9]  Jörg Otte,et al.  MYCN Function in Neuroblastoma Development , 2021, Frontiers in Oncology.

[10]  O. Delattre,et al.  Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Muselli,et al.  Hypoxia Predicts Poor Prognosis in Neuroblastoma Patients and Associates with Biological Mechanisms Involved in Telomerase Activation and Tumor Microenvironment Reprogramming , 2020, Cancers.

[12]  S. Parodi,et al.  The Over-Expression of E2F3 Might Serve as Prognostic Marker for Neuroblastoma Patients with Stage 4S Disease , 2020, Diagnostics.

[13]  Jo Lynne Rokita,et al.  Telomere Maintenance Mechanisms Define Clinical Outcome in High-Risk Neuroblastoma , 2020, Cancer Research.

[14]  H. Yao,et al.  The E2F family as potential biomarkers and therapeutic targets in colon cancer , 2020, PeerJ.

[15]  X. Zou,et al.  Regulation of E2F Transcription Factor 3 by microRNA-152 Modulates Gastric Cancer Invasion and Metastasis , 2020, Cancer management and research.

[16]  M. Capasso,et al.  Genomic coamplification of CDK4/MDM2/FRS2 is associated with very poor prognosis and atypical clinical features in neuroblastoma patients , 2019, Genes, chromosomes & cancer.

[17]  J. Johnsen,et al.  Neuroblastoma—A Neural Crest Derived Embryonal Malignancy , 2019, Front. Mol. Neurosci..

[18]  A. Di Cataldo,et al.  Stage 4 s neuroblastoma: features, management and outcome of 268 cases from the Italian Neuroblastoma Registry , 2019, Italian Journal of Pediatrics.

[19]  K. Ohtani,et al.  Mitochondrial protein E2F3d, a distinctive E2F3 product, mediates hypoxia-induced mitophagy in cancer cells , 2019, Communications Biology.

[20]  F. Westermann,et al.  A mechanistic classification of clinical phenotypes in neuroblastoma , 2018, Science.

[21]  O. Delattre,et al.  Age-dependency of the prognostic impact of tumor genomics in localized resectable MYCN non-amplified neuroblastomas Report from the SIOPEN Biology Group on the LNESG Trials , 2018 .

[22]  T. Hocking,et al.  Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients , 2018, Journal of the National Cancer Institute.

[23]  Mariano J. Alvarez,et al.  Cross-Cohort Analysis Identifies a TEAD4-MYCN Positive Feedback Loop as the Core Regulatory Element of High-Risk Neuroblastoma. , 2018, Cancer discovery.

[24]  D. Rickman,et al.  The Expanding World of N-MYC-Driven Tumors. , 2018, Cancer discovery.

[25]  M. Rubin,et al.  Differential impact of RB status on E2F1 reprogramming in human cancer , 2017, The Journal of clinical investigation.

[26]  J. Rehg,et al.  MYCN induces neuroblastoma in primary neural crest cells , 2017, Oncogene.

[27]  Long-Bang Chen,et al.  MiRNAs and E2F3: a complex network of reciprocal regulations in human cancers , 2017, Oncotarget.

[28]  F. Purrello,et al.  Altered expression of miRNAs and methylation of their promoters are correlated in neuroblastoma , 2016, Oncotarget.

[29]  F. Berthold,et al.  Advances in Risk Classification and Treatment Strategies for Neuroblastoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  E. Tokunaga,et al.  The 1,2-Diaminocyclohexane Carrier Ligand in Oxaliplatin Induces p53-Dependent Transcriptional Repression of Factors Involved in Thymidylate Biosynthesis , 2015, Molecular Cancer Therapeutics.

[31]  May D. Wang,et al.  Comparison of RNA-seq and microarray-based models for clinical endpoint prediction , 2015, Genome Biology.

[32]  J. Shohet,et al.  Neuroblastoma: molecular pathogenesis and therapy. , 2015, Annual review of medicine.

[33]  A. Vicha,et al.  Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification , 2014, British Journal of Cancer.

[34]  F. Berthold,et al.  Significance of clinical and biologic features in Stage 3 neuroblastoma: A report from the International Neuroblastoma Risk Group project , 2014, Pediatric blood & cancer.

[35]  Roland Eils,et al.  Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers , 2014, Clinical Cancer Research.

[36]  O. Delattre,et al.  Clinical Characteristics and Outcome of Patients with Neuroblastoma Presenting Genomic Amplification of Loci Other than MYCN , 2014, PloS one.

[37]  V. Pistoia,et al.  Intratumoral diversity of telomere length in individual neuroblastoma tumors , 2014, Oncotarget.

[38]  A Garaventa,et al.  Treatment of children over the age of one year with unresectable localised neuroblastoma without MYCN amplification: results of the SIOPEN study. , 2013, European journal of cancer.

[39]  Michael A. Dyer,et al.  Neuroblastoma: developmental biology, cancer genomics and immunotherapy , 2013, Nature Reviews Cancer.

[40]  Jinghui Zhang,et al.  Association of age at diagnosis and genetic mutations in patients with neuroblastoma. , 2012, JAMA.

[41]  T. McDonnell,et al.  The RB-E2F1 pathway regulates autophagy. , 2010, Cancer research.

[42]  Qiang Yu,et al.  The E2F family and the role of E2F1 in apoptosis. , 2009, The international journal of biochemistry & cell biology.

[43]  Gudrun Schleiermacher,et al.  Overall genomic pattern is a predictor of outcome in neuroblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  Barbara Hero,et al.  The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  M. Knowles,et al.  Inactivation of the Rb pathway and overexpression of both isoforms of E2F3 are obligate events in bladder tumours with 6p22 amplification , 2008, Oncogene.

[46]  R. Stallings,et al.  MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells , 2007, Oncogene.

[47]  B. Hero,et al.  Neuroblastoma , 2007, The Lancet.

[48]  C. Cooper,et al.  Role of E2F3 expression in modulating cellular proliferation rate in human bladder and prostate cancer cells , 2007, Oncogene.

[49]  A. Nicholson,et al.  Nuclear overexpression of the E2F3 transcription factor in human lung cancer. , 2006, Lung cancer.

[50]  David G Johnson,et al.  Distinct and Overlapping Roles for E2F Family Members in Transcription, Proliferation and Apoptosis. , 2006, Current molecular medicine.

[51]  Jing Xu,et al.  Expression of transcription factor E2F1 and telomerase in glioblastomas: mechanistic linkage and prognostic significance. , 2005, Journal of the National Cancer Institute.

[52]  V. Gorgoulis,et al.  Involvement of E2F transcription factor family in cancer. , 2005, European journal of cancer.

[53]  K. Helin,et al.  The E2F family: specific functions and overlapping interests , 2004, The EMBO journal.

[54]  R. Wooster,et al.  Amplification and overexpression of E2F3 in human bladder cancer , 2004, Oncogene.

[55]  H. Shimada,et al.  The International Neuroblastoma Pathology Classification. , 2003, Pathologica.

[56]  W. Lutz,et al.  E2F Proteins Regulate MYCN Expression in Neuroblastomas* , 2003, The Journal of Biological Chemistry.

[57]  W. London,et al.  MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  P. V. Rao,et al.  Applied Survival Analysis: Regression Modeling of Time to Event Data , 2000 .

[59]  K K Matthay,et al.  The International Neuroblastoma Pathology Classification (the Shimada system) , 1999, Cancer.

[60]  F. Berthold,et al.  Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. , 1993, Progress in clinical and biological research.

[61]  F. Speleman,et al.  Neuroblastoma: A Tough Nut to Crack. , 2016, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[62]  J. Maris,et al.  Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations , 2016, Cancer.